Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.

7 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

Many European hospitals fail to routinely test people at risk of HIV infection

A new study reveals that many European hospitals fail to routinely test people who may be at risk of an HIV-infection. If tests were more widely offered in the healthcare system, fewer HIV-patients would go unnoticed, especially in Northern Europe.

21 Nov 2015

Patients with kidney failure at increased risk of developing different types of cancer

For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology, suggest the need for persistent cancer screening and prevention in these patients.

13 Nov 2015

Drug combination produces long-term responses in patients with mantle cell lymphoma

New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma.

13 Nov 2015

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma.

11 Nov 2015

$Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented$

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

6 Nov 2015

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

A novel immunotherapy clinical trial underway now at The University of Kansas Cancer Center has enrolled the first patients in the world to receive what many doctors and researchers believe is the future of cancer treatment.

4 Nov 2015

Bacterium that causes Q fever associated with increased risk of lymphoma

The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American Society of Hematology.

13 Oct 2015

Malaria protein could one day help stop cancer

Scientists at the University of British Columbia, Vancouver Coastal Health and the BC Cancer Agency have discovered a protein from malaria that could one day help stop cancer in its tracks.

13 Oct 2015

Danish researchers face possible breakthrough in fight against cancer

The hunt for a vaccine against malaria in pregnant women has provided an unexpected side benefit for Danish researchers, namely what appears to be an effective weapon against cancer. The scientists behind the vaccine aim for tests on humans within four years.

13 Oct 2015

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Comparisons of cancer patients' survival and care in Europe up to 2007 show that although more patients are surviving for at least five years after diagnosis, there are large variations between countries, which are particularly significant in cancers of the blood.

26 Sep 2015

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

A study, published online in Blood, the Journal of the American Society of Hematology, reports that bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy.

22 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

HUYA Bioscience International (HUYA) today announced expanding clinical trials with its lead cancer drug, HBI-8000, starting with a Phase 1 combination trial in support of a breast cancer program to be conducted in the United States.

3 Sep 2015

Investigational topical drug shows promise in patients with early stage cutaneous T cell lymphoma

Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) - a rare type of non-Hodgkin lymphoma that affects the skin.

7 Aug 2015

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Hetero Group, one of India's leading generic pharmaceutical companies and one of the world's largest global producer of anti-retroviral drugs for HIV/AIDS treatment, today announces the successful launch of its biosimilar 'Rituximab' under the brand name MABALL in India.

5 Aug 2015

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.

4 Aug 2015

Moffitt researchers analyze participation rate of patients in pharmacogenomic trials

Cancer therapy has evolved from a "one-size-fits-all" type of treatment plan to a personalized approach based on a patient's type of cancer, the protein and genetic markers found in their tumors and their response to therapy. Important aspects of the personalized approach are pharmacogenomic studies that analyze associations between genetic variations and patient drug responses.

29 Jul 2015

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically significant increased risk, however a small increased risk could not be excluded, according to a study in the July 21 issue of JAMA.

22 Jul 2015

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

New approaches to treating leukemia, lymphoma and myeloma

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Many European hospitals fail to routinely test people at risk of HIV infection

Patients with kidney failure at increased risk of developing different types of cancer

Drug combination produces long-term responses in patients with mantle cell lymphoma

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

Bacterium that causes Q fever associated with increased risk of lymphoma

Malaria protein could one day help stop cancer

Danish researchers face possible breakthrough in fight against cancer

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

Investigational topical drug shows promise in patients with early stage cutaneous T cell lymphoma

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Moffitt researchers analyze participation rate of patients in pharmacogenomic trials

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in